Journals / Anatolian Current Medical Journal / 2026 / Volume: 6 Issue: 4

FGF-21 Level is higher in patients with breast cancer, a candidate for a new biomarker?

Zeynep Şahiner(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, GERİATRİ BİLİM DALI)0000-0003-1256-4412
Anara Karaca(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0003-2006-3853
Filiz Bakar Ateş(ANKARA ÜNİVERSİTESİ, ANKARA TIP FAKÜLTESİ)0000-0003-2809-8946
Gökhan Giray Akgül(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA DR. ABDURRAHMAN YURTASLAN ONKOLOJİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0002-0592-7521
Mehmet Ali Gülçelik(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, GÜLHANE TIP FAKÜLTESİ, GÜLHANE TIP PR. (ANKARA))0000-0002-8967-7303
Neşe Ersöz Gülçelik(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, GÜLHANE TIP FAKÜLTESİ, GÜLHANE TIP PR. (ANKARA))0000-0001-8212-5752
Pages
—
Publication Date
2024-07-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: FGF-21 is thought to have significant and beneficial effects on glucose. lipid and energy metabolism. as well as slowing the growth of cancer cells. and may later be used as a biological marker for breast cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Fibroblast Growth Factor 21 (FGF-21) is a member of the FGF family involved in biological processes such as embryonic development. cell growth. morphogenesis. tissue repair. tumour growth and invasion. with mitogenic and cytogenetic activity at 19q13.33.Breast cancer is a deadly and increasing disease in women. and recent studies have shown a relationship between some cancers. including breast cancer. and hormones secreted from adipose tissue.The aim of the present study was the measurement of FGF-21 levels in patients with breast cancer and its association with breast cancer.
📊
Key Findings & Data:Methods: The study included 39 patients with newly diagnosed breast cancer and 39 healthy controls.
💡
Conclusion & Impact:Conclusion: FGF-21 is thought to have significant and beneficial effects on glucose. lipid and energy metabolism. as well as slowing the growth of cancer cells. and may later be used as a biological marker for breast cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:FGF-21 · Breast Cancer · Obesity

Abstract

Aims: Fibroblast Growth Factor 21 (FGF-21) is a member of the FGF family involved in biological processes such as embryonic development. cell growth. morphogenesis. tissue repair. tumour growth and invasion. with mitogenic and cytogenetic activity at 19q13.33.Breast cancer is a deadly and increasing disease in women. and recent studies have shown a relationship between some cancers. including breast cancer. and hormones secreted from adipose tissue.The aim of the present study was the measurement of FGF-21 levels in patients with breast cancer and its association with breast cancer. Methods: The study included 39 patients with newly diagnosed breast cancer and 39 healthy controls. During the patients’ routine blood tests. a venous blood sample was taken and the serum levels of FGF-21 were determined by ELISA. Results: Demographic and laboratory data were compared between the newly diagnosed breast cancer group and the control group. The control group consisted of 39 participants with a mean age of 52.49 ± 7.02 years. In the patient group. 39 participants with a mean age of 52.15 ± 6.21 years were included in the study. there was no statistical difference regarding age(p>0.05).In the control group. the mean FGF-21 level was 121.35 ± 88.4 pg/ml. while the mean FGF-21 level in the patient group was 171 ± 117.45 pg/ml. a statistically significant difference was detected(p value=0.036). Conclusion: FGF-21 is thought to have significant and beneficial effects on glucose. lipid and energy metabolism. as well as slowing the growth of cancer cells. and may later be used as a biological marker for breast cancer.

🔖

Cite This Article

Şahiner, Z., Karaca, A., Ateş, F. B., Akgül, G. G., Gülçelik, M. A., Gülçelik, N. E. (2024). FGF-21 Level is higher in patients with breast cancer, a candidate for a new biomarker?. Anatolian Current Medical Journal, Volume: 6 Issue: 4. https://doi.org/10.38053/acmj.1498225

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Xue F, Michels KB. Diabetes metabolic syndrome and breast cancer: a review of the current evidence. Am J Clin Nutr. 2007;86(3):823-835.
  2. Balkau B, Valensi P, Eschwège E, Slama G. A review of the metabolic syndrome. Diabetes Metab. 2007;33(6):405-413.
  3. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293-297.
  4. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer. 2006;119(1):236-238.
  5. Falk LE, Liu J, Li YI, Lewis MJ, Demark-WW, Hurst DR. Globular adiponectin enhances invasion in human breast cancer cells. Oncol Lett. 2016;11(1):633-641.
  6. Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26(3):271-281.
  7. Luo Y, McKeehan WL, Stressed liver and muscle call on adipocytes with FGF21.Front Endocrinol. 2013;18(4):194.
  8. Abdulrahman GO Jr, Rahman GA. Epidemiology of breast cancer in europe and Africa. J Cancer Epidemiol. 2012;27:915610. doi: 10.1155/2012/915610
  9. Bjorge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1737-1745.
  10. Lin ZL, Tian H, Lam KS, Lin S. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17(5):779-789.
  11. Fukumoto S. Actions and mode of actions of FGF19 subfamily members. Endocr J. 2008;55(1):23-31.
  12. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635.
  13. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246-1253.
  14. Huang X,Yu C, Jin C, et al. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog. 2006;45(12):934-942.
  15. Ping Q, Yan R, Cheng X, et al. Cancer-associated fibroblasts: overview, progress, challenges, and directions. Cancer Gene Ther. 2021;28(9):984-999. Epub Erratum in: Cancer Gene Ther. 2021;28(9):1074.
  16. Ewendt F, Feger M, Föller M. Role of fibroblast growth factor 23 (FGF23) and αklotho in cancer. Front Cell Dev Biol. 2021;14(8): 601006.